PGRMC1 and breast carcinoma: In line with this observation, the antagonist of PKA, KT5720, enhanced the P4-evoked Ca2+ entry in all the triple breast cancer cell types evaluated (Figure 6A), so it did the silencing of PGRMC1 in MDA-MB-231 cells and MCF7 cells.